Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
Not intended for US, Canada or UK-based media
Darmstadt, Germany (ots/PRNewswire) -
- Eight high priority immuno-oncology clinical development studies
ongoing or expected to commence in 2019, including studies in
non-small cell lung and biliary tract cancers
- Merck will receive an upfront payment of EUR300 million and is
eligible for potential development milestone payments of up to
EUR500 million triggered by data from the M7824 lung cancer
program, plus future approval and commercial milestones of up to
EUR2.9 billion for a total potential deal value of up to EUR3.7
billion
Merck, a leading science and technology company, and GSK, a
science-led global healthcare company, today announced that the
companies have entered into a global strategic alliance to jointly
develop and commercialize M7824 (bintrafusp alfa*). M7824 is an
investigational bifunctional fusion protein immunotherapy that is
currently in clinical development, including potential registration
studies, for multiple difficult-to-treat cancers. This includes a
Phase II trial to investigate M7824 compared with pembrolizumab as a
first-line treatment in patients with PD-L1 expressing advanced
non-small cell lung cancer (NSCLC).
Darmstadt, Germany (ots/PRNewswire) -
- Eight high priority immuno-oncology clinical development studies
ongoing or expected to commence in 2019, including studies in
non-small cell lung and biliary tract cancers
- Merck will receive an upfront payment of EUR300 million and is
eligible for potential development milestone payments of up to
EUR500 million triggered by data from the M7824 lung cancer
program, plus future approval and commercial milestones of up to
EUR2.9 billion for a total potential deal value of up to EUR3.7
billion
Merck, a leading science and technology company, and GSK, a
science-led global healthcare company, today announced that the
companies have entered into a global strategic alliance to jointly
develop and commercialize M7824 (bintrafusp alfa*). M7824 is an
investigational bifunctional fusion protein immunotherapy that is
currently in clinical development, including potential registration
studies, for multiple difficult-to-treat cancers. This includes a
Phase II trial to investigate M7824 compared with pembrolizumab as a
first-line treatment in patients with PD-L1 expressing advanced
non-small cell lung cancer (NSCLC).
Anzeige
To view the Multimedia News Release, please click: https://www.m
ultivu.com/players/uk/8491551-merck-and-gsk-announce-global-alliance/
M7824 is designed to simultaneously target two immuno-suppressive
pathways, transforming growth factor-? (TGF-?) trap and an
anti-programmed cell death ligand-1 (PD-L1), that are commonly used
by cancer cells to evade the immune system. Bifunctional antibodies
aim to increase efficacy above and beyond that achieved with
individual therapies or combinations of individual therapies.1 M7824
has the potential to offer new ways to fight difficult-to-treat
cancers beyond the established PD-1/PD-L1 class. In addition to use
as a single agent, M7824 is also being considered for use in
combination with other assets from the pipelines of both companies.
"Our bifunctional fusion protein M7824 has the potential to bring
new answers to patients living with cancer. Together with GSK we aim
to drive a paradigm shift in the treatment of cancer as the leader in
this novel class of immunotherapies," said Belén Garijo, Member of
the Executive Board and CEO Healthcare of Merck. "GSK clearly emerged
as the ideal partner due to their strong commitment to oncology, and
the complementary talent and capabilities they will bring to our
alliance. We now look forward to harnessing the full potential of
ultivu.com/players/uk/8491551-merck-and-gsk-announce-global-alliance/
M7824 is designed to simultaneously target two immuno-suppressive
pathways, transforming growth factor-? (TGF-?) trap and an
anti-programmed cell death ligand-1 (PD-L1), that are commonly used
by cancer cells to evade the immune system. Bifunctional antibodies
aim to increase efficacy above and beyond that achieved with
individual therapies or combinations of individual therapies.1 M7824
has the potential to offer new ways to fight difficult-to-treat
cancers beyond the established PD-1/PD-L1 class. In addition to use
as a single agent, M7824 is also being considered for use in
combination with other assets from the pipelines of both companies.
"Our bifunctional fusion protein M7824 has the potential to bring
new answers to patients living with cancer. Together with GSK we aim
to drive a paradigm shift in the treatment of cancer as the leader in
this novel class of immunotherapies," said Belén Garijo, Member of
the Executive Board and CEO Healthcare of Merck. "GSK clearly emerged
as the ideal partner due to their strong commitment to oncology, and
the complementary talent and capabilities they will bring to our
alliance. We now look forward to harnessing the full potential of
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte